TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Nursing home operators say more residents are arriving on GLP-1 drugs, now prescribed for conditions beyond diabetes and weight loss. Providers see possible health benefits but face added monitoring demands and difficult payment questions, particularly when Medicare coverage does not apply. A temporary Medicare Part D bridge program runs through 2027, while a permanent version has been delayed.
Nursing home operators are seeing more residents arrive on GLP-1 medications, with prescriptions extending beyond diabetes and weight loss to other chronic conditions, according to a report by Skilled Nursing News. The broader use is prompting facilities to strengthen clinical monitoring while confronting uncertain coverage and potentially high medication costs.
At Venza Care, about 30% to 40% of newly admitted residents are taking GLP-1 drugs, said Lisa Chubb, the company’s chief nursing officer. She said the share is higher at facilities with more short-stay residents. Chubb described use as expanding toward cardiovascular prevention, metabolic health and other chronic conditions; those are reported prescribing trends, not evidence that the drugs benefit every nursing home resident.
Venza holds weekly “nutrition at risk” meetings with interdisciplinary teams, and uses electronic health record assessments to document medication review, resident education and weight monitoring, Chubb said. Registered dietitians are involved in overseeing residents who take the medications. The added procedures reflect concern that weight loss can bring risks for people already vulnerable to frailty or muscle weakness.
Coverage depends on a resident’s circumstances. Jessie McGill of the American Association for Post-Acute Care Nursing said a Medicare Part D bridge program covers certain GLP-1s prescribed for weight loss, with an additional $50 monthly fee. She identified Wegovy, Zepbound and Foundeo as eligible drugs. The program was extended through 2027; a more permanent proposal, called BALANCE, was delayed without a new implementation date.
Medication Costs Reach Facility Budgets
GLP-1 use affects more than a resident’s prescription list: it can shape care planning, staff education and facility finances. McGill said residents with Medicare and Medicaid may still struggle to pay the bridge program’s monthly fee. For residents covered under Medicare Part A during a nursing home stay, the facility may be responsible for the medication cost, she said.
Jody O’Mara, chief nursing officer at Journey Skilled Nursing, said high-cost drugs become an operator expense when pharmacy services are arranged through a joint venture. She said she believes the benefits outweigh the costs, but the financial exposure may influence which residents a facility accepts and how it approaches assessments and quality programs. That is an operator’s view; the report does not provide comparative cost or outcome data establishing the overall financial balance.
Popular right now
Dreame H12 Pro Wet and Dry Vacuum Mop
Ninja Luxe Café Mini Plus Espresso and Drip Coffee Machine with AutoFroth, Stainless Steel (ES351)
Apple AirPods Max 2 Wireless Over-Ear Headphones – Midnight
As an affiliate, we earn on qualifying purchases.
A Temporary Medicare Coverage Bridge
The coverage pathway described in the report is limited rather than universal. According to McGill, the bridge program applies to certain residents with Medicare Part D who receive an eligible GLP-1 for weight loss and have not already been prescribed one for diabetes. She said GLP-1s prescribed for diabetes are covered under Part D. Eligibility also involves BMI tiers and other chronic conditions that help determine the stated medical need.
The distinction matters when a resident enters a facility. A drug that is not eligible for the bridge program can leave the nursing home facing a high expense for a resident covered under Part A, McGill said. She said expanding Medicare consolidated billing to include high-cost medications such as GLP-1s could be a future policy option; providers can currently bill Medicare Part B directly for certain excluded drugs, including some chemotherapy and dialysis medications.
““We see a lot of our new admissions coming in with GLP-1s. Initially it was used solely for weight loss and diabetes, but now we’re seeing it trend in other directions as well.””
— Lisa Chubb, chief nursing officer for Venza Care
Coverage and Resident Risks Remain
The timing and terms of permanent coverage remain unsettled: BALANCE has been delayed without a future start date, and the bridge program is temporary. The report does not specify what coverage will look like after 2027 or whether Congress will change consolidated billing.
Clinical suitability also varies. Stenson said nursing home residents may already have frailty, multiple chronic conditions, nutrition concerns or limits on daily function, so weight loss is not necessarily a desirable outcome for every person. She cited nausea, vomiting, constipation and dehydration as possible adverse effects. The report does not provide facility-wide data on outcomes, side-effect rates or total spending, and it does not establish which residents should receive the drugs.
Operators Track Coverage and Care
Facilities will need to continue reviewing medication use, resident nutrition and weight changes while the temporary coverage arrangement remains in effect. The next policy milestone is not set: CMS has delayed the more permanent BALANCE program, while the bridge program is scheduled to continue through 2027. Providers and residents will also be watching whether Congress considers changes to consolidated billing for high-cost drugs.
For now, nursing home leaders interviewed by Skilled Nursing News describe GLP-1s as both a potential care option and a growing operational responsibility. The scale of that responsibility will depend on who qualifies for coverage, what residents can afford and how facilities manage clinical risks.
Key Questions
Why are more nursing home residents taking GLP-1 medications?
Operators report use extending beyond diabetes and weight loss to other chronic conditions, including cardiovascular and metabolic health. The report does not establish that treatment is appropriate or beneficial for every resident.
Does Medicare cover GLP-1 drugs for nursing home residents?
Coverage depends on the prescription and the resident’s Medicare arrangement. McGill said a Part D bridge program covers certain drugs prescribed for weight loss, with a $50 monthly fee, while GLP-1s prescribed for diabetes are covered under Part D. Eligibility restrictions apply.
Who pays when a resident is covered by Medicare Part A?
McGill said the nursing home may be responsible for the medication cost for a resident on Medicare Part A. The expense can be high if the drug is not eligible for the bridge program.
What health concerns do nursing homes monitor?
Staff may monitor weight and nutrition, and consider risks tied to frailty or muscle weakness. Stenson also cited nausea, vomiting, constipation and dehydration as possible adverse effects.
Source: skillednursingnews.com
